Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.50.
CLBS has been the subject of several research analyst reports. Brookline Capital Management initiated coverage on Caladrius Biosciences in a research report on Monday, May 25th. They set a “buy” rating and a $7.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Caladrius Biosciences in a report on Friday, May 15th. Zacks Investment Research cut Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Monday, May 11th. Dawson James cut Caladrius Biosciences from a “buy” rating to a “neutral” rating in a report on Monday, May 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.50 price target on shares of Caladrius Biosciences in a report on Friday, May 8th.
An institutional investor recently bought a new position in Caladrius Biosciences stock. Summit Trail Advisors LLC bought a new position in Caladrius Biosciences Inc (NASDAQ:CLBS) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,730 shares of the biotechnology company’s stock, valued at approximately $32,000. Summit Trail Advisors LLC owned approximately 0.14% of Caladrius Biosciences at the end of the most recent quarter. Institutional investors own 6.60% of the company’s stock.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.09). On average, research analysts predict that Caladrius Biosciences will post -1.51 earnings per share for the current year.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.